Sonova further extends offering of Sennheiser-branded   hearing solutions with All-Day Clear

Media Release

Stäfa (Switzerland), June 20, 2023 Sonova Holding AG, a leading provider of hearing care solutions, today announces the upcoming US launch of Sennheiser All-Day Clear, a new self-fitting hearing aid which provides consumers with the simplicity of an over-the-counter (OTC) purchase alongside optional support from a hearing care professional (HCP). This further extends the offering of Sennheiser-branded solutions to cover a broad spectrum of early hearing needs, from prevention and situational support through to OTC hearing aids. Sennheiser All-Day Clear and other solutions from this range will be available to US HCP customers to help them build relationships with consumers earlier.

Arnd Kaldowski, CEO of Sonova, says: Just over a year after our acquisition of the Sennheiser Consumer Division, we have now met an important strategic goal of providing Sennheiser-branded hearing solutions which are available to consumers across the early stages of their hearing journey. With the upcoming launch of AllDay Clear, we are offering the HCP a great opportunity to connect to consumers sooner and the option to expand their engagement over time. 

Martin Grieder, Group Vice President Consumer Hearing at Sonova, adds: We are now very well placed to meet the needs of modern, tech-savvy consumers, thanks to the broad range of medical and consumer distribution channels across Sonova, as well as a growing range of hearing solutions under the Sennheiser brand. With Sennheiser All-Day Clear, we bring consumers ready-to-wear hearing aids with clear, vibrant sound and seamless optimization of dialogue, alongside self-fitting features which can be customized from the comfort of their smartphone and an upgrade option for further support by a HCP. 

Approved by the US Food and Drug Administration (FDA) as an OTC hearing aid, Sennheiser All-Day Clear will give US consumers access to powerful assistive hearing technology and self-fitting features. The device is available in two unique designs and consumers can customize it, guided by the intuitive AllDayClear app. With the goal of simplifying consumers lives, music can be streamed from Bluetooth® enabled devices, including iOS® and Android mobile phones. Furthermore, those consumers seeking the peace of mind that a local HCP can provide have the option to purchase the In-Clinic Care Package. Powered by Sonova technology, the hearing aids feature intelligent scene detection that monitors the persons environment for seamless optimization of speech and music, all provided by a compact rechargeable device. 

All-Day Clear is part of a broader range of Sennheiser-branded hearing solutions:

• A growing range of early entry devices, which are designed to provide hearing support in specific situations, such as understanding speech in a noisy restaurant with Conversation Clear Plus, or on TV with TV Clear. Sonova is currently expanding their distribution further, with two dedicated options for its HCP customers (ConC 400 and TVS 200 respectively).
• The SoundProtex and SoundProtex Plus, high-fidelity hearing protection earplugs which use advanced membrane filter technology to help prevent hearing damage at concerts and loud environments.

Sennheiser is a registered trademark of Sennheiser electronic GmbH & Co. KG and is used under license by Sonova
The Bluetooth® word mark is a registered trademark owned by the Bluetooth SIG, Inc. and any use of such marks by Sonova AG is under license. IOS is a trademark of Cisco, Inc. Android is a trademark of Google Inc. 

End  

Disclaimer
This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of managements views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside Sonovas control. Should one or more of these risks or un-certainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sonova undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law.

About Sonova
Sonova is a global leader in innovative hearing care solutions: from personal audio devices and wireless communication systems to audiological care services, hearing aids and cochlear implants. The Group was founded in 1947 and is headquartered in Stäfa, Switzerland.

Sonova operates through four businesses Hearing Instruments, Audiological Care, Consumer Hearing and Cochlear Implants and the core brands Phonak, Unitron, AudioNova, Sennheiser (under license) and Advanced Bionics as well as recognized regional brands. The Groups globally diversified sales and distribution channels serve an ever growing consumer base in more than 100 countries.

In the 2022/23 financial year, the Group generated sales of CHF 3.7 billion, with a net profit of CHF 658 million. Over 17,000 employees are working on achieving Sonovas vision of a world where everyone enjoys the delight of hearing.

For more information please visit www.sonova.com.

Sonova shares (ticker symbol: SOON, Security no: 1254978, ISIN: CH0012549785) have been listed on the SIX Swiss Exchange since 1994. The securities of Sonova have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the U.S. Securities Act), or under the applicable securities laws of any state of the United States of America, and may not be offered or sold in the United States of America except pursuant to an exemption from the registration requirements under the U.S. Securities Act and in compliance with applicable state securities laws, or outside the United States of America to non-U.S. Persons in reliance on Regulation S under the U.S. Securities Act.